Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne.

1 December 2023. doid: 10.1080/09546634.2022.2138691

Thiboutot DM, Craft N, Rissmann R, Gatlik E, Souquières M, Jones J, Loesche C

CJM112 is a potent anti-IL-17A monoclonal antibody, whose clinical efficacy in psoriasis was recently documented. This study aimed to assess the effect of IL-17A blockade, using CJM112, in patients with moderate to severe acne.

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact

Therapeutic Areas

challenges

methods

Trial Services

Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne.

Advancing the boundaries of clinical drug development